“Are They Ready Yet?”: release criteria for autologous CAR T cells

Competing interests

AJ: Consulting: Kite/Gilead. Research Support (Institutional): Kite/Gilead, Allogene Therapeutics. OO: Consultancy and advisory board: Pfizer, Kite, Gilead, Janssen, TGR therapeutics, ADC, Novartis, Epizyme, Nektar, Cargo, Caribou, Autolus, Bioheng, Allogene. Institution funding: Kite, Pfizer, Daichi Sankyo, Cargo, Caribou, Sana, Century, Allogene. Honoraria: Pfizer, Gilead, ADC. BD: Institutional research funding: Janssen, Angiocrine, Pfizer, Poseida, MEI, Orcabio, Wugen, Allovir, Adicet, BMS, Molecular template, Atara. Consultancy/Advisor: MJH BioScience, Arivan Research, Janssen, ADC therapeutics, Gilead, GSK, Caribou, Roche, Autolus.

留言 (0)

沒有登入
gif